FDA Approves Lantus SoloStar - A New Prefilled Disposable InsulinPen For Use With Lantus In People With Type 1 And Type 2 DiabetesNew Delivery Method Available for LANTUS(R) (insulin glargine [rDNA origin] injection)
BRIDGEWATER, N.J., April 30, 2007 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today that the U.S. Food and Drug Administration (FDA) approved Lantus SoloStar(R), a new prefilled disposable insulin pen for once-daily 24- hour insulin LANTUS(R) (insulin glargine) for the treatment of hyperglycemia in people with type 1 or type 2 diabetes.
The introduction of Lantus SoloStar(R) offers a convenient option for administering once-daily 24-hour LANTUS(R), the number one prescribed insulin in the world. LANTUS(R) in the Lantus SoloStar(R) pen provides diabetes patients with an alternative to the traditional needle and syringe for insulin therapy. Lantus SoloStar(R) is the only disposable insulin pen that allows patients to administer doses from 1 up to 80 units, in one injection.
"Sanofi-aventis is committed to working with the diabetes community to develop new technologies intended to help make the difficult task of managing diabetes simpler and more convenient," explained Gilles Lhernould, Senior Vice President Industrial Affairs, sanofi-aventis. "Lantus SoloStar(R) is the result of more than 4 years of intensive development and testing with diabetes patients, doctors and nurses," he added.
Lantus SoloStar(R) is expected to be available in pharmacies in 2007.
"Insulin therapy for people with type 2 diabetes is generally initiated very late in the course of the disease, leaving many patients with high blood glucose levels," explained Satish Garg, MD, Chief, Young Adult Clinics, Professor of Pediatrics & Medicine, Barbara Davis Center for Diabetes, University of Colorado School of Medicine, Denver, USA. "Easier delivery devices like disposable pens can make using insulin more convenient."
New Lantus SoloStar(R) Test Results Published
In a separate but related event, sanofi-aventis also announced today the publication of Lantus SoloStar(R) dose accuracy and injection force test results. These results appear in the March issue of the journal Expert Opinion on Drug Delivery. All testing was performed in a laboratory setting and did not include testing on patients.
Dose accuracy testing was conducted according to International Organization for Standardization (ISO) test standards to evaluate whether the Lantus SoloStar(R) pen would repeatedly deliver the dialed dose under a range of conditions. The results demonstrated that Lantus SoloStar(R) accurately and consistently delivered the dialed dose of insulin well within the ISO standard. Injection force testing was performed to measure the force required to dispense a known volume of insulin within a fixed time period compared to other currently marketed insulin pens. The results showed that the Lantus SoloStar(R) pen had a mean total injection force that was more than 30% less than other frequently used disposable pens(1).
About Lantus SoloStar(R)
Lantus SoloStar(R) is a prefilled, disposable insulin pen that allows patients to dial their dose from 1 to 80 units of insulin. Lantus SoloStar(R) should be kept in cool storage (36 degrees F - 46 degrees F [2 degrees C - 8 degrees C]) until first use. Once in use, it can be kept at room temperature, as long as it remains below 77 degrees F, and can be used for up to 28 days.
Diabetes is a chronic, widespread condition in which the body does not produce or properly use insulin - the hormone needed to convert glucose (sugar) into energy. More than 230 million people worldwide are living with the disease. This number is expected to rise to a staggering 350 million within 20 years.(2) It is estimated more than 20 million Americans have diabetes, including an estimated 6.2 million who remain undiagnosed(3). At the same time, approximately half of those diagnosed are not achieving the general blood sugar control standard of A1C <7% recommended by the American Diabetes Association (ADA)(4). The A1C test measures average blood glucose levels over a two- to three-month period.
LANTUS(R), the number one prescribed insulin, is the only 24-hour insulin approved exclusively for use once a day. Most insulins have what is called a "peak of action." The peak refers to the time at which insulin reaches its maximum effect in the body. With LANTUS(R), the insulin is released into the bloodstream at a relatively constant rate throughout the day and night; therefore it has no pronounced peak.
Important Safety Information for LANTUS(R)
Prescription Lantus(R) is for adults with type 2 diabetes or adults and children (6 years and older) with type 1 diabetes who require long-acting insulin for the control of high blood sugar.
OptiClik(R) is a reusable insulin delivery device (insulin pen) for use with a 3-mL Lantus(R) cartridge (U-100). Needles and the OptiClik(R) pen must not be shared.
DO NOT DILUTE OR MIX LANTUS(R) WITH ANY OTHER INSULIN OR SOLUTION. It will not work as intended, and you may lose blood sugar control, which could be serious. Do not change your insulin without talking with your doctor. The syringe must not contain any other medication or residue. You should not use Lantus(R) if you are allergic to insulin. Lantus(R) is a long-acting insulin you inject just once a day, at the same time each day. You must test your blood sugar levels while using an insulin such as Lantus(R).
The most common side effect of insulin, including Lantus(R), is hypoglycemia, which may be serious. Other possible side effects may include injection site reactions, including changes in fat tissue at the injection site, and allergic reactions, including itching and rash. In rare cases, some allergic reactions may be life threatening. Tell your doctor about other medicines and supplements you are taking because they can change the way insulin works.
Please visit www.Lantus.com for full prescribing information.
Sanofi-aventis is one of the world leaders in the pharmaceutical industry, ranking number one in Europe. Backed by a world-class R&D organisation, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular, thrombosis, oncology, metabolic diseases, central nervous system, internal medicine and vaccines. Sanofi-aventis is listed in Paris and in New York .
Forward Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include financial projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions. Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward- looking information and statements. These risks and uncertainties include those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in sanofi-aventis' annual report on Form 20-F for the year ended December 31, 2006. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.
Global contact: Anna Radjanova, MD +33 6 07 28 61 63, U.S. Contacts: Terri Pedone, +1-908-981-6562,email@example.com Terri.Pedone@sanofi-aventis.com
Amy Ba, +1-908-981-6563, US.GLA.07.03.0
Posted: April 2007